

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Checking for updates and scope: before scope consultation (to be completed by the Developer and submitted with the draft scope for consultation)

1.1 Is the proposed primary focus of the guideline a population with a specific communication or engagement need, related to disability, age, or other equality consideration? Y/N

If so, what is it and what action might be taken by NICE or the developer to meet this need? (For example, adjustments to committee processes, additional forms of consultation.)

Not applicable as no scoping process was carried out for this update.

1.2 Have any potential equality issues been identified during the check for an update or during development of the draft scope, and, if so, what are they?

Not applicable as no scoping process was carried out for this update.

1.3 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee?

Not applicable.

Completed by Developer: Susan Spiers

Date: 12/8/20

Approved by NICE quality assurance lead: Christine Carson

Date: 8/9/20

2.0 Checking for updates and scope: after consultation (to be completed by the Developer and submitted with the revised scope)

2.1 Have any potential equality issues been identified during consultation, and, if so, what are they?

Not applicable as no scoping process was carried out for this update.

2.2 Have any changes to the scope been made as a result of consultation to highlight potential equality issues?

Not applicable.

2.3 Have any of the changes made led to a change in the primary focus of the guideline which would require consideration of a specific communication or engagement need, related to disability, age, or other equality consideration?

If so, what is it and what action might be taken by NICE or the developer to meet this need? (For example, adjustments to committee processes, additional forms of consultation)

Not applicable as no scoping process was carried out for this update.

Completed by Developer: Susan Spiers

Date: 12/8/20

Approved by NICE quality assurance lead: Christine Carson

Date: 8/9/20

3.0 Guideline development: before consultation (to be completed by the Developer before consultation on the draft guideline)

3.1 Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Not applicable

3.2 Have any **other** potential equality issues (in addition to those identified during the scoping process) been identified, and, if so, how has the Committee addressed them?

The committee identified the following potential equality issues:

- Age – children under the age of five have a greater risk of diabetic ketoacidosis
- Race – Black and minority ethnic children present to hospital with diabetic ketoacidosis more frequently
- Sex - girls and young women are more likely to develop diabetic ketoacidosis
- Socio-economic factors - Children and young people in the most deprived areas of the UK are more likely to be hospitalised for diabetic ketoacidosis

The committee considered these equality issues but were of the opinion that these did not directly impact on fluid therapy for the management of diabetic ketoacidosis. These equality issues would not influence the optimal route of fluid administration, type of fluid (including additives) or the rate and volume for rehydration in children and young people with diabetic ketoacidosis.

3.3 Have the Committee's considerations of equality issues been described in the guideline for consultation, and, if so, where?

Yes – in the “other factors the committee took into account” section of the committee's discussion of the evidence.

3.4 Do the preliminary recommendations make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the

barriers to, or difficulties with, access for the specific group?

The committee did not identify anything in the preliminary recommendations to make it more difficult in practice for a specific group to access services compared with other groups.

3.5 Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

3.6 Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in box 3.4, or otherwise fulfil NICE's obligation to advance equality?

None.

Completed by Developer: Susan Spiers

Date: 12/8/20

Approved by NICE quality assurance lead: Christine Carson

Date: 8/9/20